Abstract: A medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a ?-glucan component and a silver-containing component is disclosed. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or as a surgical mesh. Methods for manufacturing the medical compositions described herein are also provided. The invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site.

Abstract: A medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a ?-glucan component and a silver-containing component is disclosed. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or as a surgical mesh. Methods for manufacturing the medical compositions described herein are also provided. The invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site.

Abstract: The present invention discloses an immunostimulating agent that may be applied to various surgical devices to promote rapid healing and the ready acceptance and integration of the surgical devices with the body tissues at the surgical site.

Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Abstract: A medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a &bgr;-glucan component and a silver-containing component is disclosed. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or as a surgical mesh. Methods for manufacturing the medical compositions described herein are also provided. The invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site.

Abstract: The present invention discloses an immunostimulating agent that may be applied to various surgical devices to promote rapid healing and the ready acceptance and integration of the surgical devices with the body tissues at the surgical site.

Abstract: A topical composition for healing treatment of burns and wounds and scarring therefrom has as the active ingredient cereal-derived (1-3) (1-4) &bgr;-D-glucan at about 0.5-15 w/w percent. The composition may be formulated in various forms with creams and gels being preferred for application to the skin.

Abstract: Disclosed are novel G-CSF receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Abstract: A topical composition for healing treatment of burns and wounds and scarring therefrom has as the active ingredient cereal-derived (1-3) (1-4) .beta.-D-glucan at about 0.5-15 w/w percent. The composition may be formulated in various forms with creams and gels being preferred for application to the skin.

Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids 119 to 133 have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.

Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) in which segments of the polypeptide sequence of the human IL-3 polypeptide have been replaced by segments of the murine (mouse) interleukin-3 (mIL-3) polypeptide to form human/murine chimeric hybrid polypeptides. The human/mouse IL-3 may have amino acid deletions at the N-terminus or the C-terminus or at both the N- and C- termini and in some cases may also contain additional amino acid substitutions or deletions. The human/murine IL-3 muteins retain at least one biological activity of native hIL-3 and may also exhibit an improved side effects profile such as a reduction in the stimulation of leukotriene release or histamine release. The invention also relates to pharmaceutical compositions containing the h/m IL-3 hybrids and methods for using them.

Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) in which segments of the polypeptide sequence of the human IL-3 polypeptide have been replaced by segments of the murine (mouse) interleukin-3 (mIL-3) polypeptide to form human/murine chimeric hybrid polypeptides. The human/mouse hybrid IL-3 may have amino acid deletions at the N-terminus or the C-terminus or at both the N- and C- termini and in some cases may also contain additional amino acid substitutions or deletions. The human/murine IL-3 muteins retain at least one biological activity of native hIL-3 and may also exhibit an improved side effects profile such as a reduction in the stimulation of leukotriene release or histamine release. The invention also relates to pharmaceutical compositions containing the h/m IL-3 hybrids and methods for using them.